Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer

Documenti analoghi

• Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
  di: Botting, Gregory M., et al.
  Pubblicazione: (2015)
• A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
  di: Miyoshi, Seigo, et al.
  Pubblicazione: (2015)
• Comparison of Epithelial Mesenchymal Transition Mediated Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cell Lines with Wild Type EGFR and Mutant Type EGFR
  di: Iderzorig, Tsatsral, et al.
  Pubblicazione: (2018)
• Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade
  di: Luttman, Jillian Hattaway, et al.
  Pubblicazione: (2021)
• A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
  di: Zhang, Nana, et al.
  Pubblicazione: (2017)